Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy
Recent advances in the application of CRISPR/Cas gene editing technology to enhance the antitumor activity of CAR-T cells against solid tumors are summarized and the key challenges currently faced are discussed.